MEDI1341 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04449484 (ClinicalTrials.gov)	August 4, 2020	23/4/2019	Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: MEDI1341;Other: Placebo	AstraZeneca	NULL	Active, not recruiting	40 Years	85 Years	All	25	Phase 1	United States
2	NCT03272165 (ClinicalTrials.gov)	October 17, 2017	29/6/2017	Single Ascending Dose Study of MEDI1341 in Healthy Volunteers	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.	Parkinson's Disease	Drug: MEDI1341;Drug: Placebo	AstraZeneca	Covance;MMS Holdings, Inc;Catalent	Completed	18 Years	80 Years	All	49	Phase 1	United States;United Kingdom